NCT00162188View on ClinicalTrials.gov

An Expanded Access Study of Oral Liquid Efavirenz in the Treatment of Children With HIV Infection: Canada

NO_LONGER_AVAILABLEEXPANDED_ACCESS
Timeline

Start Date

May 31, 2001

Primary Completion Date

December 31, 2010

Study Completion Date

December 31, 2010

Conditions
HIV Infection
Interventions
DRUG

Efavirenz

Oral Solution, Oral 200 - 600 mg (weight based), once daily. Until further treatment with Sustiva Oral Solution is not warranted.

Trial Locations (4)

T6G 2J3

Local Institution, Edmonton

V6H 3N1

Local Institution, Vancouver

M5G 1X8

Local Institution, Toronto

H3T 1C5

Local Institution, Montreal

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT00162188 - An Expanded Access Study of Oral Liquid Efavirenz in the Treatment of Children With HIV Infection: Canada | Biotech Hunter | Biotech Hunter